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A B S T R A C T
Nitric oxide (NO) has been implicated in the pathogenesis of migraine and treatment with its exogenous donor gly-
ceryl trinitrate (GTN) represents widely accepted experimental »migraine model«. In this study, glyceryl trinitrate was
administered intraperitoneally to carps, serum nitrite and nitrate levels were determined, permeability of blood-brain
barrier was investigated, and histological changes of brain tissue were analyzed. Serum nitrite and nitrate levels dis-
played characteristic biphasic pattern with moderate initial increase and maximal terminal increase, suggesting the
GTN-induced endogenous NO synthesis. Increased permeability of the blood-brain barrier in GTN-treated animals was
determined based on Evans blue capillary leakage into the brain tissue. Histological analysis revealed changes consis-
tent with vasodilatation and oedema. Our study strongly supports the importance of the NO role in the pathogenesis of
migraine attacks and increase in blood-brain barrier permeability during the attack. The study has also provided evi-
dence that this mechanism of action is conserved to the lower vertebrate.
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Introduction
The free radical nitric oxide (NO) has been implicated
in the pathophysiology of migraine based on several evi-
dence derived from human and experimental animal
studies. Glyceryl trinitrate (GTN) is an organic nitrate
which releases NO via metabolic biotransformation in
the target tissue. Intravenous infusion of nitroglycerin
triggers migraine-like headaches, suggesting a specific
role in primary headache pathogenesis1–3. Furthermore,
inhibition of NO-synthase relieves acute migraine at-
tacks4. More indirect evidence is provided by studies
showing that platelet levels of cyclic GMP, the second
messenger of NO, as well as NO metabolites nitrate/ni-
trite, are increased in migraineurs and that they rise fur-
ther during attacks5,6.
Nitric oxide is an important biological endogenous
synthesized messenger molecule, playing a role in a vari-
ety of biological processes including neurotransmission,
immune defense and the regulation of cell death (apop-
tosis)7. It is produced in neurons, glia, endothelial cells,
and macrophages from and by various (NOS) and by
sequential reduction of inorganic nitrate8. Multiple re-
ceptors and neurotransmitters can release NO leading to
vasodilatation and possible extravasations subsequent to
the secondary release of other mediators9,10. There is
some evidence that represents NO as a key coupling com-
pound which links cortical spreading depression (CSD)
changes in cerebral blood flow and metabolism. It was
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suggested that NO synthase is up-regulates by cellular
depolarisation/depression occuring during CSD11.
It was demonstrated that glyceryl trinitrate enhances
CSD-induced NO release in treated animals12. CSD’s as-
sociation with multiphasic NO release13 was also demon-
strated.
This study was designed to assess the effect of glyce-
ryl trinitrate on blood-brain barrier changes, vasodilata-
tion and neurogenic inflammation suggesting their role
in the pathogenesis of migraine. Organic nitrate was ex-
perimentally administered to carps in order to elicit the
NO formation.
Material and Methods
Animals
A year old forty eight carps, free of major diseases,
were brought to the Department for Biology and Pathol-
ogy of Fish and Bees, Veterinary Faculty, University of
Zagreb from the fish farm »Topli~ica«, Novi Marof, Croa-
tia. The fish weighted 574–908 g. During 4-weeks of ad-
aptation preceding to the experiment, the fish were kept
in a 660–l plastic pool under steady, slow circulation of
dechlorinated tap water and were fed commercial food.
Measurement of serum nitrite, nitrate and
total nitrite/nitrate
One mg/kg b.w. of glyceryl trinitrate (Trinitrosan
amp., Merck Pharma GmbH) was intraperitonealy in-
jected to carps (n=35). Caudal vessels were punctured
with disposable plastic injectors, immediately after injec-
tion (0 h) and after 1, 3, 6 and 8 hours. The samples were
centrifuged for 15 min at 2500 x g at room temperature
and serum was filtered through a 10 kDa filter (Millipore
Co Ltd., MA, USA). Serum samples were kept at –20 °C
prior to the nitrite/nitrate analysis.
Total nitrite/nitrate in in the carp serum was deter-
mined using the nitrite/nitrate colorimetric assay kit
(Cayman Chemical Company, MI, USA) according to the
manufacturer’s instructions. Forty ml of the serum was
briefly mixed with 40 mL of assay buffer, 10 mL of enzyme
cofactor and 10 mL of nitrate reductase, and incubated at
room temperature for 3 h (conversion of nitrate to ni-
trite). After 10 min of incubation in Griess reagent at
room temperature the absorbance was measured at 560
nm using Tecan Ultra Fluorescence Spectrophotometer
(Tecan Co., USA). Total nitrite/nitrate in serum of carps
was determined using the nitrite/nitrate colorimetric as-
say kit (Cayman Chemical Company, MI, USA) according
to manufacturer instruction. Briefly, 40 mL of serum was
mixed with 40 mL of assay buffer, 10 mL of enzyme cofac-
tor and 10 mL of nitrate reductase, and incubated at room
temperature for 3 h (conversion of nitrate to nitrite). Af-
ter 10 min of incubation in Griess reagent at room tem-
perature the absorbance was measured at 560 nm using
Tecan Ultra Fluorescence Spectrophotometer (Tecan Co.,
USA).
The level of total nitrite/nitrate and nitrite was calcu-
lated from standard curves of increasing nitrate and ni-
trite concentrations. Each experiment was performed in
triplicate. The final results are expressed as mM of the to-
tal nitrite/nitrate and nitrite.
Measurement of Evans blue Dye (EBD) for
BBB integrity
Permeability of Evans blue Dye was evaluated for
BBB integrity in accordance with a modified method de-
scribed by Rapoport et al.14 BBB integrity was measured
in 25 animals, 15 from the treatment group and 10 from
the control group.
Carps were intraperitonealy injected with 1 mg/kg
b.w. glyceryl trinitrate (Trinitrosan amp., Merck Pharma
GmbH). Immediately after injection, carps were retur-
ned to the plastic pool. Carps in the control group were
intraperitonealy injected with the saline. Approximately
6 hours later carps were anesthetized with MS-222 (Sig-
ma Aldrich Chemie Gmbh, Steinheim) and 2% Evans
blue Dye saline (Sigma Aldrich Chemie Gmbh, Stein-
heim) 2 mL/kg body weight was injected intracardialy, al-
lowed to circulate for a couple of minutes. Pericardial
cavity of the carps was opened and perfused with saline
solution via bulbus arteriosus followed by 4% formalde-
hyde in PBS. After the experiment, anesthetized carps
were bled by cutting the gill arches. Their brains were re-
moved immediately after sacrifice and post-fixed in 4%
formaldehyde in PBS solution. All brains were photo-
graphed and the degree of Evans blue staining was
graded on a scale of 0–3 as previously described14. Zero
was assigned for no stain uptake, 1 for light staining of
the surface and cortical layers, 2 for darker diffuse corti-
cal staining and light staining of the white matter, and 3
if deep blue staining of grey and white matters was ob-
served.
Histopathology
The brains of 23 fish (13 treated with GTN and 10
controls) were fixed in 10% buffered formalin for the
purpose of histological examination. The fixed material
was embedded in paraffin wax and serially sectioned.
The 6-mm thick sections were stained with hematoxylin
and eosin (HE).
Statistical analysis
The data were statistically analyzed in accordance
with the standard statistical programme (SPSS, EXCEL
for Windows). The total nitrate/nitrite and nitrite levels
in the serum were statistically analysed by means of
one-way analysis of variance (ANOVA), followed by a
multiple comparison procedure (Tukey test). The level of
P<0.05 was considered statistically significant. The re-
sults were represented as mean±SEM.
The Mann-Whitney test was used for within-group
comparisons. P<0.05 was considered significant.
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Evans blue scores were statistically evaluated using a
Mann-Whitney test. P<0.05 was interpreted statistically
significant.
Results
There were no mortalities in any of the experimental
groups. Three animals (1 from the treatment and 2 from
the control group) from those that were subjected to the
Evans blue dye (EBD) measurement for BBB integrity
were excluded from the experiment. In case that blue col-
oration of the gill has not been observed immediately af-
ter injection of the dye the heart puncture in these ani-
mals was considered unsuccessful.
The total nitrite/nitrate level at 0 hours was 187.7±
19.51 mmol (mean±SD), significantly higher than in 3-
hours group (111.7±12.88 mmol), and significantly lower
than in 6-hours (251.3±63.99 mmol) and 8-hours (255.2±
25.81 mmol) groups. In the 1st hour of GTN administra-
tion the level was 185.3±15.89 mmol, insignificantly lower
than in the 0-group, significantly higher than in 3-hours
group, and significantly lower than in 6- and 8-hours
groups. The 3-hours group showed a marked level reduc-
tion, while 6- and 8-hours groups had maximal nitrite/ni-
trate levels (Figure 1).
The nitrate concentration curve is similar to the total
nitrite/nitrate. At 0 hours it was 180.2±25.76 mmol, sig-
nificantly higher than in the 3-hours group (124.6±7.13
mmol), and significantly lower than in 6-hours (232.4±
63.84 mmol) and 8-hours (236.9±89.12 mmol) groups. Ni-
trate level in the 1st hour group was 182.9±15.39 mmol,
which is insignificantly higher than in the 0-hour group
and significantly higher than in the 3-hours group but
significantly lower than in 6- and 8-hours groups. The
level was significantly reduced in the 3-hours group,
while 6- and 8-hours groups demonstrated maximal ni-
trite/nitrate levels (Figure 2).
Nitrite levels were markedly lower than nitrate levels
and reached maximal values in the 3-hours group (14.28±
9.627 mmol) and 8-hours group (16.17±5.935 mmol), which
had levels statistically higher than all other groups
(0-hour group 8.11±3.529 mmol, 1-hour group 5.452±
2.507 mmol, 6-hours group 4.014±2.252 mmol) (Figure 3).
Eight of control animals had an Evans blue score of 0
and two control animals were given a score of 1. Nine of
the treated animals were given the score of 3 and the re-
maining six animals the score of 2 (Table 1).
Evans blue scores for the treatment group were sig-
nificantly higher then for the control group (p<0.05).
Our results did not include leakage of the dye in the ar-
eas of circumventricular organs (Figure 4).
Findings of the histological brain examination of all
GTN treated animals in the study had characteristics of
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TABLE 1
EVANS BLUE SCORING IN THE GTN TREATMENT GROUP
AND THE CONTROL GROUP
Evans Blue
Score
Control Group
(n=10)
Treatment Group
(n=15)
»0« 8 0
»1« 2 0
»2« 0 6
»3« 0 9
* See the text on scoring
Fig. 1. Serum levels of total nitrate/nitrite at 0, 1, 3, 6 and 8 hours
after treatment with glyceryl trinitrate (1 mg/kg b.w.). Mean±
S.E.M. (n=7) are given. * (p<0.05), as compared to 0 hours of
treatment; a) (p<0.05), as compared to 3 hours of treatment; b)
(p<0.05) as compared to 6 hours of treatment; c) (p<0.05), as com-
pared to 8 hours of treatment.
Fig. 2. Serum nitrate levels at 0, 1, 3, 6 and 8 hours after treat-
ment with glyceryl trinitrate (1 mg/kg b.w.) Mean±S.E.M. (n=7)
are given. * (p<0.05), as compared to 0 hours of treatment; a)
(p<0.05), as compared to 3 hours of treatment; b) (p<0.05) as
compared to 6 hours of treatment; c) (p<0.05), as compared to 8
hours of treatment.
Fig. 3. Serum nitrite levels at 0, 1, 3, 6 and 8 hours after treat-
ment with glyceryl trinitrate (1 mg/kg b.w.) Mean±S.E.M. (n=7)
are given. a) (p<0.05), as compared to 3 hours of treatment; b)
(p<0.05) as compared to 6 hours of treatment; c) (p<0.05), as com-
pared to 8 hours of treatment.
vasodilatation and brain edema. In all treated animals
we detected vacuolization or spongy change of the neu-
ropil and pericellular vacuolization as well as pallor of
the tissue and swollen astrocytes (Figure 5). Small areas
of meningeal hemorrhage and leukocyte infiltration seen
in one of the treated animals, was assessed as procedural
complication/over-dosage of GTN. Brain parenchyma un-
der this finding was notably edematous. Histological
findings in the control group were normal.
Discussion
The exact molecular mechanism of migraine remains
to be fully clarified. The NO has emerged as an impor-
tant mediator of a neurogenic cranial vessel inflamma-
tory response that ultimately might result in headache.
According to Olesen et al., nitroglycerin can trigger
migraine-like headaches, suggesting a specific role in pri-
mary headache pathogenesis1. There is a pharmacologic
but indirect clinical evidence for the NO hypothesis.
Sumatriptan can terminate the nitroglycerin-induced mi-
graine. Calcium channel blockers may work by reducing
NO synthase activity and thus levels of NO. Lassen et al.
published a double-blind, placebo-controlled study on
L-methylarginine, a non-specific NO synthase inhibitor
in the treatment of acute migraine. They found that
headache was relieved in the treated group as compared
to the placebo group 4.
The purpose of this study was to determine whether
the increased permeability of the blood-brain barrier
(BBB) after GTN-treatment is associated with over ex-
pression/induced nitric oxide biosynthesis. Because the
extremely short half-life of NO makes its detection diffi-
cult, we sought to determine the predominant role of NO
in blood brain barrier (BBB) reversible disruption by
studying stable NO metabolites, nitrite and nitrate ions.
In our study the total nitrite/nitrate and nitrate serum
concentrations showed biphasic pattern with moderate
increase in 0 (1) hour of GTN administration and mar-
ked increase after 6 and 8 hours. The nitrite levels were
markedly lower than nitrate ones and showed maximal
values in the 3- and 8-hours groups. Theoretically, the ni-
trate and nitrite standard curves should be identical, as
nitrate is converted to nitrite, but in vivo slight or
greater differences almost always exist due to incomplete
reduction of nitrate15. Since according to current studies
and our results the ratio of nitrite to nitrate in biologic
fluids is variable and unpredictable, the best index of NO
production appears to be the total of nitrate and nitrite16.
The reason for delayed (6- and 8-hours groups) elevation
in nitrite/nitrate levels probably includes GTN-evoked
endogenous NO synthesis. This biphasic pattern of bio-
activated NO release following GTN infusion corresponds
with previous studies17–19. GTN is an organic nitrate
with a short plasma half-life (1–4 min), although its
half-life can reach 2 hours in a slice of lipophilic brain
tissue20,21. It is metabolized to NO within cells by a com-
bination of glutathione-S-transefrase, cytochrome P450
and thiol reactions. NO synthesizes endogenously by ni-
tric oxide synthases (NOS) using L-arginine as a subs-
trate22. Release of NO from blood vessels, perivascular
nerve endings and brain tissue is proposed to be a molec-
ular trigger mechanism of spontaneous migraine pain23.
There are reports of inducible NOS (iNOS) mRNA up-re-
gulation beginning at 2 hours and increasing at 4, 6 and
10 hours following the GTN infusion24. Thus, biphasic
pattern must be due to a phenomenon inherent in the
mechanism of the NO generation induced by GTN.
Histological findings revealed vasodilatation charac-
teristics. The NO contributes to vasodilatation observed
in cortical spreading depression13. Transient arterial di-
latation during CSD was reduced by approximately 50%
during application of NO-synthase inhibitor25,26. It is
well known that NO activates cytoplasmic guanylate
cyclase, hence causing an increase in cyclic guanosine
monophosphate, a decrease in intracellular calcium and
vasodilatation27.
We have also detected Evans blue leakage indicating
BBB opening, as well as (initially) vasogenic oedema in
the brain tissue in the 6-hour group. With regard to mo-
lecular mechanisms, cortical spreading depression up-
regulates a variety of gene for expression of COX-2,
TNF-[alpha] and IL-1[beta], galanin and metalloprotei-
nases28. Besides, NO have been implicated in MMP acti-
vation. The basal lamina contains extracellular matrix
molecules such as type IV collagen, laminin, and fibro-
nectin, most of which are substrates for MMPs, especially
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Fig. 4. Evans blue stained brain in a treated carp.
Fig. 5. H&E stained brain preparation of treated carp showing
dilated blood vessels containing blood, with thinned and elon-
gated, but regular endothelial cells. Oedema in adjacent neural
tissue is also displayed.
MMP-2 and MMP-929,30. The activation of metalloprotei-
nases leads to leakage of the blood-brain barrier, allowing
potassium, (more) nitric oxide, adenosine and other pro-
ducts released by cortical spreading depression to reach
and sensitize the dural perivascular trigeminal affe-
rents28. We believe that the NO was the mediator of de-
layed changes in BBB permeability observed in this stu-
dy. In previous studies, leakage of plasma proteins from
blood vessels was first detected 4 hours after GTN infu-
sion, and this can be suppressed by administration a spe-
cific type II NOS inhibitor29.
On the grounds of our experiment and previous inves-
tigations of experimental migraine models, we strongly
suggest the implication of the NO in the migraine patho-
physiology. The precise mechanism of the NO-activated
cascade remains to be clarified. The existing evidences
may set novel targets for treatments that would either
prevent or abort headache. This study has also shown
that the mechanism of NO elicitation and BBB perme-
ability changes are conserved to the lower vertebrate.
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POVE]ANA PROPUSNOST KRVNO-MO@DANE BARIJERE MOZGA [ARANA
(CYPRINUS CARPIO L.) NAKON PRIMJENE GLICERIL TRINITRATA
S A @ E T A K
Du{ik (II) oksid (NO) je impliciran u patogenezi migrene, a tretiranje njegovim egzogenim donorom gliceril trinitra-
taom (GTN), predstavlja op}enito prihva}en eksperimetalni »model migrene«. U na{em smo pokusu {arane tretirali s
gliceril trinitratom intraperitonealno te smo odredili koncentraciju serumskih nitrita i nitrata, ispitali propusnost krvno-
-mo`dane barijere i analizirali histopatolo{ke promjene u tkivu mozga. Koncentracija serumskih nitrita i nitrata imala
je karakteristi~an bifazi~ni obrazac s blagim inicijalnim i maksimalnim terminalnim pove}anjem {to sugerira GTN-
-induciranu endogenu NO sintezu. GTN-tretirane `ivotinje su pokazale pove}anu propusnost krvno-mo`dane barijere,
{to smo utvrdili na temelju istjecanja Evans blue boje u mo`dano tkivo. Histopatolo{kom analizom ustanovljene su
promjene karakteristi~ne za vazodilataciju i edem. Na{e istra`ivanje sna`no podupire va`nu ulogu NO u patogenezi
migrenskog napadaja, odnosno pove}anje propusnosti krvno-mo`dane barijere u migrenskom napadaju. Ovo istra`i-
vanje tako|er dokazuje da je ovaj mehanizam djelovanja konzerviran do ni`ih kralje{njaka i zbog toga ga mo`emo
smatrati va`nim.
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